Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 12-Month Low - Here's What Happened

Key Points

• Supernus Pharmaceuticals shares fell 4.4%, hitting a new 52-week low of $40.38 and closing near $40.44, below both its 50-day and 200-day moving averages.
• Analyst sentiment is mixed but leans cautious: the stock has an average “Hold” rating and a consensus price target of $62.40, while recent firms issued “strong sell,” “sell,” and “hold” ratings.
• The company missed quarterly earnings expectations, reporting a loss of $1.01 per share versus an expected profit of $0.42, despite revenue of $219.06 million that exceeded estimates and grew 32.4% year over year.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report)'s stock price reached a new 52-week low on Wednesday. The stock traded as low as $40.38 and last traded at $40.44, with a volume of 595,855 shares traded. The stock had previously closed at $42.01.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on SUPN shares. Zacks Research lowered shares of Supernus Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Monday, October 5th. Weiss Ratings reiterated a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a report on Monday, September 21st. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, Cantor Fitzgerald boosted their target price on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an "overweight" rating in a report on Thursday, July 9th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $62.40.

Supernus Pharmaceuticals Trading Down 4.4%

The firm has a fifty day moving average price of $44.22 and a 200 day moving average price of $46.60. The firm has a market cap of $2.34 billion, a PE ratio of -20.93, a price-to-earnings-growth ratio of 0.79 and a beta of 0.55.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of $0.42 by ($1.43). Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The firm had revenue of $219.06 million for the quarter, compared to analyst estimates of $205.31 million. During the same period in the previous year, the firm posted $0.40 EPS. The company's revenue was up 32.4% compared to the same quarter last year. As a group, equities analysts predict that Supernus Pharmaceuticals, Inc. will post 1.97 earnings per share for the current year.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of SUPN. Mystic Asset Management Inc. purchased a new position in Supernus Pharmaceuticals during the second quarter worth about $1,181,000. Bank of America Corp DE raised its stake in shares of Supernus Pharmaceuticals by 37.2% in the 1st quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company's stock valued at $36,918,000 after acquiring an additional 193,479 shares during the period. BlackRock Inc. purchased a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter valued at approximately $434,871,000. Allworth Financial LP purchased a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter valued at approximately $2,357,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Supernus Pharmaceuticals in the 2nd quarter worth approximately $1,298,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for diseases of the central nervous system (CNS). The company's portfolio has primarily addressed epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on differentiated formulations and products designed to improve treatment convenience and patient outcomes.

Supernus markets Oxtellar XR (oxcarbazepine extended-release) for the treatment of partial-onset seizures and Trokendi XR (topiramate extended-release) for certain seizure disorders and the prevention of migraine headaches.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.